Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Viridian Therapeutics (NASDAQ: VRDN) entered a royalty financing and amended credit facility to raise up to $300 million. The company received a $55 million upfront payment and may receive up to $115 million in near-term milestones tied to positive VRDN-003 REVEAL topline data and U.S. veligrotug approval. Proceeds plus existing cash are expected to fully fund commercial launches of veligrotug and VRDN-003. Viridian expects to submit the veligrotug BLA imminently and now projects VRDN-003 topline readouts in REVEAL-1 Q1 2026 and REVEAL-2 Q2 2026. An amended Hercules credit facility provides up to $300 million, including a required $50 million draw at closing.
Viridian Therapeutics (Nasdaq: VRDN) announced on October 2, 2025 that its Compensation Committee approved inducement grants of non-qualified stock options to purchase an aggregate of 147,650 shares to 4 new employees, with a Grant Date of October 1, 2025. The options were granted outside the company's 2016 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Exercise price equals the closing price on the Grant Date. Vesting: 25% at one year, then monthly over 36 months, subject to continued employment.
Viridian Therapeutics (NASDAQ: VRDN) announced significant progress in its thyroid eye disease (TED) portfolio. The company has completed enrollment for both REVEAL-1 and REVEAL-2 phase 3 clinical trials for VRDN-003, exceeding target enrollment with 132 and 204 patients respectively. Topline data is expected in H1 2026.
Key developments include: USPTO granting composition patent for VRDN-003 until 2041, planned veligrotug BLA submission in November 2025 with potential mid-2026 launch under Priority Review, and positive VRDN-006 data showing consistent IgG reductions. The company's VRDN-008 IND submission remains on track for year-end 2025.
Viridian Therapeutics (Nasdaq: VRDN), a biopharmaceutical company focused on rare diseases, has granted non-qualified stock options to purchase 139,600 shares of common stock to 4 new employees as inducement awards. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months.
The company is currently advancing multiple clinical programs, including veligrotug (VRDN-001) and VRDN-003 for thyroid eye disease (TED), both reporting positive Phase 3 trial results. Additionally, Viridian is developing novel FcRn inhibitors (VRDN-006 and VRDN-008) for potential autoimmune disease treatments.
Viridian Therapeutics (Nasdaq: VRDN) reported significant progress in Q2 2025, highlighting key developments for its thyroid eye disease (TED) treatments. The company's lead drug candidate veligrotug received Breakthrough Therapy Designation in May 2025, with planned BLA submission in 2H 2025 and expected U.S. launch in 2026.
Key achievements include a $70 million upfront licensing deal with Kissei Pharmaceutical for Japan rights to veligrotug and VRDN-003, with potential additional milestones of $315 million plus royalties. The company reported strong durability data for veligrotug, with 70% of proptosis responders maintaining response at 52 weeks.
Financially, Viridian maintains a robust cash position of $563.4 million as of June 30, 2025, providing runway into 2H 2027. R&D expenses increased to $86.6 million in Q2 2025, up from $56.2 million year-over-year, reflecting expanded clinical trial activities.
Viridian Therapeutics (Nasdaq: VRDN), a biopharmaceutical company specializing in rare diseases, has announced the approval of inducement grants to 4 new employees. The grants consist of non-qualified stock options to purchase 181,450 shares of common stock, with an exercise price equal to the closing price on August 1, 2025.
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments. The grants were made outside the company's Amended and Restated 2016 Equity Incentive Plan but follow its terms and conditions.
Notably, Viridian is advancing multiple candidates for thyroid eye disease (TED), including veligrotug (VRDN-001) and VRDN-003, both reporting positive Phase 3 trial results. The company is also developing novel FcRn inhibitors VRDN-006 and VRDN-008 for autoimmune diseases.
Viridian Therapeutics (NASDAQ:VRDN) has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical for the development and commercialization of veligrotug and VRDN-003 in Japan. The deal includes an upfront payment of $70 million and potential additional payments of up to $315 million in milestones.
Both compounds are anti-IGF-1R antibodies targeting thyroid eye disease (TED), with VRDN-003 being a potential best-in-class subcutaneous treatment. The agreement grants Kissei exclusive rights in Japan, with Kissei responsible for all development, regulatory, and commercialization activities. Viridian will receive tiered royalties ranging from the 20s to mid-30s percent on net sales in Japan.
The collaboration leverages Viridian's TED portfolio and Kissei's expertise in rare disease commercialization in Japan. Veligrotug has already demonstrated positive topline data in the THRIVE and THRIVE-2 Phase 3 trials.
Viridian Therapeutics (NASDAQ: VRDN), a biopharmaceutical company focused on rare diseases, announced an inducement grant of 175,000 stock options to a new employee on July 1, 2025. The grant, approved under Nasdaq Rule 5635(c)(4), will vest over four years with a 25% initial vest after one year.
The company is currently advancing multiple candidates for thyroid eye disease (TED), including veligrotug (VRDN-001) and VRDN-003, both reporting positive Phase 3 trial results. Additionally, Viridian is developing novel FcRn inhibitors VRDN-006 and VRDN-008 for potential autoimmune disease treatments.